Proteolytic cleavage of elafin by 20S proteasome may contribute to inflammation in acute lung injury

Thorax

Volumn 68, Issue 4, 2013, Pages 315-321

  Kerrin, Aoife ^a   Weldon, Sinéad ^a   Chung, Allen Hung Kang ^b   Craig, Thelma ^a   Simpson, A John ^c   O'Kane, Cecilia M ^a   McAuley, Danny Francis ^a   Taggart, Clifford C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

20S PROTEASOME; ELAFIN; EPOXOMICIN; LEUKOCYTE ELASTASE; PROTEASOME; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCUBATION TIME; INFLAMMATION; LUNG LAVAGE; MASS SPECTROMETRY; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FAMILY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WESTERN BLOTTING;

EID: 84875215644     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202536     Document Type: Article

References (37)

1. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005;353:1685-93. (Pubitemid 41464707)
2. Tremblay GM, Sallenave JM, Israel-Assayag E, et al. Elafin/elastase- specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung. Am J Respir Crit Care Med 1996;154(4 Pt 1):1092-8.
3. Sallenave JM, Shulmann J, Crossley J, et al. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994;11:733-41.
4. van Wetering S, van der Linden AC, van Sterkenburg MA, et al. Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol 2000;278:L51-8. (Pubitemid 30104174)
5. Reid PT, Marsden ME, Cunningham GA, et al. Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett 1999;457:33-7. (Pubitemid 29387404)
6. Simpson AJ, Cunningham GA, Porteous DJ, et al. Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum Gene Ther 2001;12:1395-406. (Pubitemid 32881345)
7. Tsunemi M, Kato H, Nishiuchi Y, et al. Synthesis and structure-activity relationships of elafin, an elastase-specific inhibitor. Biochem Biophys Res Commun 1992;185:967-73.
8. Guyot N, Zani ML, Berger P, et al. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. Biol Chem 2005;386:391-9. (Pubitemid 41447602)
9. Molhuizen HO, Alkemade HA, Zeeuwen PL, et al. SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking. J Biol Chem 1993;268:12028-32. (Pubitemid 23168166)
10. Nara K, Ito S, Ito T, et al. Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed 'cementoin'. J Biochem 1994;115:441-8. (Pubitemid 24096454)
11. Simpson AJ, Maxwell AI, Govan JR, et al. Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett 1999;452:309-13. (Pubitemid 29301766)
12. Sallenave JM, Cunningham GA, James RM, et al. Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 2003;71:3766-74. (Pubitemid 36753697)
13. Butler MW, Robertson I, Greene CM, et al. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 2006;281:34730-35. (Pubitemid 46036512)
14. Petty TL. Protease mechanisms in the pathogenesis of acute lung injury. Ann N Y Acad Sci 1991;624:267-77.
15. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982;3:35-56. (Pubitemid 12062058)
16. Wang Z, Beach D, Su L, et al. A genome-wide expression analysis in blood identifies pre-elafin as a biomarker in ARDS. Am J Respir Cell Mol Biol 2008;38:724-32. (Pubitemid 351841574)
17. Wang Z, Chen F, Zhai R, et al. Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development. PLoS ONE 2009;4:e4380.
18. Tejera P, Wang Z, Zhai R, et al. Genetic polymorphisms of peptidase inhibitor 3 (elafin) are associated with ARDS. Am J Respir Cell Mol Biol 2009;41:696-704.
19. Guyot N, Butler MW, McNally P, et al. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem 2008;283:32377-85.
20. Guyot N, Bergsson G, Butler MW, et al. Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases. Biol Chem 2010;391:705-16.
21. Kantyka T, Latendorf T, Wiedow O, et al. Elafin is specifically inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage. Biol Chem 2009;390:1313-20.
22. Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of hydroxymethylglutaryl-CoA reductase inhibition for acute lung injury (The HARP study). Am J Respir Crit Care Med 2011;183:620-6.
23. Morris A, Kefala K, Wilkinson TS, et al. Diagnostic importance of pulmonary interleukin-1β and interleukin-8 in ventilator-associated pneumonia. Thorax 2010;65:201-7.
24. Weldon S, McNally P, McElvaney NG, et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 2009;183:8148-56.
25. Sixt SU, Adamzik M, Spyrka D, et al. Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;179:1098-106.
26. Sixt SU, Alami R, Hakenbeck J, et al. Distinct proteasome subpopulations in the alveolar space of patients with the acute respiratory distress syndrome. Mediators Inflamm 2012;2012:204250.
27. Majetschak M, Sorell LT, Patricelli T, et al. Detection and possible role of proteasomes in the bronchoalveolar space of the injured lung. Physiol Res 2009;58:363-72.
28. Matthay MA, Zimmerman GA, Esmon C, et al. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2003;167:1027-35. (Pubitemid 36408170)
29. Nobar SM, Zani ML, Boudier C, et al. Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3. FEBS J 2005;272:5883-93. (Pubitemid 41689360)
30. Iqbal SM, Ball TB, Levinson P, et al. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 2009;23:1669-77.
31. Sallenave JM, Donnelly SC, Grant IS, et al. Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome. Eur Respir J 1999;13:1029-36. (Pubitemid 29288925)
32. Sixt SU, Beiderlinden M, Jennissen HP, et al. Extracellular proteasome in the human alveolar space: a new housekeeping enzyme? Am J Physiol Lung Cell Mol Physiol 2007;292:L1280-8. (Pubitemid 47084874)
33. Vadász I, Weiss CH, Sznajder JI. Ubiquitination and proteolysis in acute lung injury. Chest 2012;141:763-71.
34. Roth GA, Moser B, Krenn C, et al. Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest 2005;35:399-403. (Pubitemid 40826839)
35. Bao J, Sato K, Li M, et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol 2001;281:H2612-8.
36. Korkmaz B, Horwitz MS, Jenne DE, et al. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010;62:726-59.
37. Shaw L, Wiedow O. Therapeutic potential of human elafin. Biochem Soc Trans 2011;39:1450-4.